A Prospective, Randomized Open-Label Study for Assessment of Antihypertensive Effect of Telmisartan Versus Cilnidipine Using Ambulatory Blood Pressure Monitoring (START ABPM Study)

Background The antihypertensive agent telmisartan is an angiotensin II receptor blocker with a terminal elimination half-life of 24 h and has a high lipophilicity, thereby enhancing its bioavailability. Another antihypertensive agent, cilnidipine is a calcium antagonist and has dual mode of action on the calcium channels. This study aimed at determining effect of these drugs on ambulatory blood pressure (BP) levels. Methods A randomized, open-label, single-center study was conducted during 2021 - 2022 on newly diagnosed adult patients with stage-I hypertension, in a mega city of India. Forty eligible patients were randomized to telmisartan (40 mg) and cilnidipine (10 mg) groups, with once daily dose administered for 56 consecutive days. Ambulatory blood pressure monitoring (ABPM) (24 h) was performed pre- and post-treatment, and the ABPM-derived parameters were compared statistically. Results Statistically significant mean reductions were observed in all BP endpoints in telmisartan group but only in 24-h systolic blood pressure (SBP), daytime and nighttime SBP, and manual SBP and diastolic blood pressure (DBP) in cilnidipine group. The mean change from baseline to day 56 between two treatment groups showed statistical significance in last 6-h SBP (P = 0.01) and DBP (P = 0.014), and morning SBP (P = 0.019) and DBP (P = 0.028). The percent nocturnal drop within and between groups was statistically nonsignificant. Also, the between group mean SBP and DBP smoothness index differed nonsignificantly. Conclusions Telmisartan and cilnidipine once daily were effective and well tolerated in the treatment of newly diagnosed stage-I hypertension. Telmisartan provided sustained 24-h BP control and may offer advantages over cilnidipine in terms of BP reductions, particularly over the 18- to 24-h post-dose period or critical early morning hours.

[1]  L. Dwivedi,et al.  Diagnosis and Treatment of Hypertension Among People Aged 45 Years and Over in India: A Sub-national Analysis of the Variation in Performance of Indian States , 2021, Frontiers in Public Health.

[2]  V. Jha,et al.  Indian guidelines on hypertension-IV (2019) , 2020, Journal of Human Hypertension.

[3]  Jackson T. Wright,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.

[4]  A. Takahara.  Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. , 2009, Cardiovascular therapeutics.

[5]  J. Basile.  Blood pressure responder rates versus goal rates: which metric matters? , 2009, Therapeutic advances in cardiovascular disease.

[6]  K. Nitta,et al.  Different Effects of L/N-Type and L-Type Calcium Channel Blockers on the Renin-Angiotensin-Aldosterone System in SHR/Izm , 2009, American Journal of Nephrology.

[7]  G. Grassi.  Sympathetic Overdrive and Cardiovascular Risk in the Metabolic Syndrome , 2006, Hypertension Research.

[8]  P. Gosse.  A Review of Telmisartan in the Treatment of Hypertension: Blood Pressure Control in the Early Morning Hours , 2006, Vascular health and risk management.

[9]  K. Matzek,et al.  A Review on Telmisartan: A Novel, Long-Acting Angiotensin II-Receptor Antagonist , 2006 .

[10]  P. Gosse,et al.  The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I) , 2006, Journal of hypertension.

[11]  Alice Stanton,et al.  Superiority of Ambulatory Over Clinic Blood Pressure Measurement in Predicting Mortality: The Dublin Outcome Study , 2005, Hypertension.

[12]  G. Bakris,et al.  Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial , 2005, Blood pressure monitoring.

[13]  P. Gosse,et al.  Reduction of early morning blood pressure surge with telmisartan compared with ramipril in mild-to-moderate hypertensive patients , 2005 .

[14]  P. Gosse,et al.  Blood pressure surge on rising , 2004, Journal of hypertension.

[15]  Y. Lacourciére,et al.  Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements , 2003, Journal of hypertension.

[16]  W. White.  Ambulatory blood-pressure monitoring in clinical practice. , 2003, The New England journal of medicine.

[17]  H. Brunner,et al.  The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview , 2002, Journal of Human Hypertension.

[18]  T. Marbury,et al.  A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. , 2000, The Canadian journal of cardiology.

[19]  J. Siché,et al.  ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension , 1999, Journal of Human Hypertension.

[20]  G. Parati,et al.  The smoothness index: A new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension , 1998, Journal of hypertension.

[21]  D. Dzielak.  Comparative pharmacology of the angiotensin II receptor antagonists. , 1998, Expert opinion on investigational drugs.

[22]  G. Bourne.  The diagnosis and management of hypertension. , 1955, Practitioner.

[23]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[24]  C. Ram,et al.  Hypertension Therapeutics Update: A Brief Clinical Summary on Azilsartan, Cilnidipine and Nebivolol , 2015 .

[25]  Y. Lacourciére,et al.  A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. , 2006, American journal of hypertension.

[26]  P. Gosse,et al.  Nocturnal blood pressure fall on ambulatory monitoring in a large international database. The "Ad Hoc' Working Group. , 1997, HYPERTENSION.